Flash Finance

Sakar Healthcare LimitedSAKARCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹961.70
MCap ₹2,111 Cr · P/E 58.5
Sakar Healthcare Limited — Stock analysis & AI research Sakar Healthcare Limited — Multibagger AI analysis Sakar Healthcare Limited — Seasonality — best & worst months Sakar Healthcare Limited — Technical indicators & charts Sakar Healthcare Limited — Technical setup — score, trend, support & resistance Sakar Healthcare Limited — Live exchange announcements
📋 High Operating Margin Stocks📋 High Profit Growth Stocks📋 Stocks With Strong Quarterly Results 📈 SuperTrend Bearish Signal 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹73 Cr
Sales · Jun 2026
+38.4% YoY
₹21 Cr
Operating Profit · Jun 2026
+67.2% YoY
29.1%
OPM % · Jun 2026
+20.7% YoY
₹10 Cr
Net Profit · Jun 2026
+120.2% YoY
₹4.62
EPS · Jun 2026
+119.0% YoY

📝 Sakar Healthcare Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Sakar Healthcare Limited reported revenue of ₹73 crore for the quarter ended June 2026 (Q1 FY27), up 38.4% from ₹53 crore in the same quarter last year, and up 2.6% sequentially over the March 2026 quarter.

Net profit rose 120.2% year-on-year to ₹10 crore, from ₹5 crore. Earnings per share (EPS) came in at ₹4.62.

Operating profit stood at ₹21 crore — an operating margin (OPM) of 29.1%, compared with 24.1% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Sakar Healthcare Limited posted revenue of ₹252 crore, a growth of 41.9% over FY25, with a net profit of ₹30 crore (up 71.8% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹272 crore with a net profit of ₹36 crore.

Valuation snapshot

At the current price of ₹961.70, SAKAR has a market capitalisation of ₹2,111 crore and a trailing P/E of about 58.5.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 23rd-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, foreign institutional investors (FIIs) 12.34%, promoters held 51.70%, domestic institutional investors (DIIs) 11.92%, public shareholders 24.04% of Sakar Healthcare Limited.

Promoter holding slipped from 52.86% to 51.70% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹2,111 Cr
Current Price ?
₹961.7
P/E ?
58.48above ind
Industry P/E ?
37.20
P/B ?
6.52
P/S ?
7.76
P/FCF ?
100.52
Enterprise Value ?
₹2,166 Cr
EV/EBITDA ?
27.97
PEG ?
1.72
Earnings Yield ?
2.4%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹272 Cr
OPM ?
28.5%
Profit after tax (TTM) ?
₹36 Cr
EPS (TTM) ?
₹16.45
ROCE ?
13.0%
ROE ?
11.1%
ROA ?
7.5%
Growth
Sales — latest qtr ?
₹73 Cr
PAT — latest qtr ?
₹10 Cr
YoY qtr sales growth ?
38.4%
YoY qtr profit growth ?
120.2%
Sales growth (3y) ?
24%
Sales growth (5y) ?
22%
Profit growth (3y) ?
34%
Profit growth (5y) ?
23%
Financial Health
Debt ?
₹55 Cr
Debt to Equity ?
0.17
Interest Coverage ?
5.8
Current Ratio ?
N/A
Ownership
Promoter holding ?
51.70%
Change in promoter holding ?
-1.16%
Pledged percentage ?
N/A
Market
Return 3 months ?
9.6%
Return 6 months ?
62.0%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 4139343743414343505358707173 +38.4% +2.6%
Operating Profit 899911111212161311192621 +67.2% -19.0%
Other Income 22101000001102 +292.0% +801.8%
Interest 22222121422222 -22.1% -30.8%
Depreciation 45445555566667 +17.4% +10.2%
Profit Before Tax 44435555655111815 +170.8% -19.3%
Net Profit 43423255655101110 +120.2% -6.7%
EPS 2.041.461.680.981.461.102.172.082.622.112.034.594.964.62 +119.0% -6.9%
OPM % 19.1% 23.1% 27.5% 24.2% 25.5% 26.0% 26.9% 27.1% 32.0% 24.1% 19.7% 26.4% 36.9% 29.1% +20.7% -21.1%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹177 Cr ₹252 Cr ₹272 Cr +41.9%
Operating Profit ₹50 Cr ₹69 Cr ₹77 Cr +37.9%
OPM % 28.17% 27.37% 28.47% -2.8%
NPM % 10.00% 12.11% 13.27% +21.1%
Other Income ₹1 Cr ₹2 Cr ₹3 Cr +102.3%
Depreciation ₹20 Cr ₹24 Cr ₹25 Cr +15.5%
Interest ₹8 Cr ₹8 Cr ₹7 Cr -5.8%
EBIT ₹30 Cr ₹45 Cr ₹53 Cr +53.4%
PBT ₹21 Cr ₹40 Cr ₹49 Cr +86.7%
Tax ₹4 Cr ₹6 Cr ₹10 Cr +70.6%
Net Profit ₹18 Cr ₹30 Cr ₹36 Cr +71.8%
EPS ₹7.97 ₹13.69 ₹16.20 +71.8%
Material Cost ₹69 Cr ₹133 Cr ₹144 Cr +91.1%
Employee Cost ₹16 Cr ₹39 Cr ₹43 Cr +145.7%
Extraordinary Items ₹-0 Cr — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 19222222 +0.0%
Reserves 154241264302 +14.4%
Borrowings 119798655 -36.0%
Other Liabilities 444743101 +134.9%
Total Liabilities 336389415481 +15.9%
Fixed Assets 267314309326 +5.5%
CWIP 60174 -76.5%
Investments 3000 —
Other Assets 607490151 +67.8%
Total Assets 336389415481 +15.9%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 33243449 +44.1%
Cash from Investing Activity -74-52-31-28 +9.7%
Cash from Financing Activity 4127-3-21 -600.0%
Net Cash Flow 00-0-0 —
Free Cash Flow -49-35221 +950.0%
CFO/OP 113%72%73%77% +5.5%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 60506373 +15.9%
Inventory Days 76121193207 +7.3%
Days Payable 12912093153 +64.5%
Cash Conversion Cycle 751163127 -22.1%
Working Capital Days -6295244 -15.4%
ROCE % 9%7%9%13% +44.4%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
FIIs 13.41%13.31%13.05%12.94%12.34% -4.6%
Promoters 52.86%52.86%52.86%52.86%51.70% -2.2%
DIIs 11.25%11.43%11.36%11.32%11.92% +5.3%
Public 22.48%22.41%22.73%22.87%24.04% +5.1%
No. of Shareholders 8,1157,5657,0699,58019,539 +104.0%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Sakar Healthcare Limited's revenue in Q1 FY27?
Sakar Healthcare Limited reported revenue of ₹73 crore for the quarter ended June 2026 (Q1 FY27), up 38.4% from ₹53 crore in the same quarter last year, and up 2.6% sequentially over the March 2026 quarter.
What was Sakar Healthcare Limited's net profit in Q1 FY27?
Net profit rose 120.2% year-on-year to ₹10 crore, from ₹5 crore. Earnings per share (EPS) came in at ₹4.62.
What is SAKAR's market capitalisation and P/E ratio?
At the current price of ₹961.70, SAKAR has a market capitalisation of ₹2,111 crore and a trailing P/E of about 58.5.
Who owns Sakar Healthcare Limited? (shareholding pattern)
As of Sep 2026, foreign institutional investors (FIIs) 12.34%, promoters held 51.70%, domestic institutional investors (DIIs) 11.92%, public shareholders 24.04% of Sakar Healthcare Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI